<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306995</url>
  </required_header>
  <id_info>
    <org_study_id>102499</org_study_id>
    <nct_id>NCT00306995</nct_id>
  </id_info>
  <brief_title>Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population</brief_title>
  <official_title>A Phase III, Open, Randomized, Multicenter, Comparative Vaccination Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of a Monovalent Candidate Pandemic Influenza A Vaccine in Individuals Over 60 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Influenza pandemics are caused by viruses that possess an Hemagglutinin molecule to which
      most of the population lacks immunity. If such virus is pathogenic to human and demonstrates
      the ability to transmit from person to person, the result is a global outbreak of disease
      that affects a high percentage of individuals in a short period of time and is likely to
      cause substantially increased mortality and morbidity in all countries of the world.
      Recently, purely avian influenza viruses, including the H5N1, H9N2 and H7N7 subtypes, have
      been directly transmitted to humans, raising concern over the possibility of a new influenza
      pandemic among the world's immunologically naive populations. In order to face this kind of
      situation, a pandemic influenza vaccine has to be developed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2005</start_date>
  <completion_date type="Actual">July 4, 2006</completion_date>
  <primary_completion_date type="Actual">July 4, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</measure>
    <time_frame>At Day 10 post Dose 1</time_frame>
    <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</measure>
    <time_frame>At Day 21 post Dose 1</time_frame>
    <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</measure>
    <time_frame>At Day 10 post Dose 1</time_frame>
    <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer lower than (&lt;) 1:10 and a post-vaccination titre higher than or equal to (≥) 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in post-vaccination titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</measure>
    <time_frame>At Day 21 post Dose 1</time_frame>
    <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer &lt; 1:10 and a post-vaccination titre ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in post-vaccination titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Factor for Influenza A Subtype H9N2</measure>
    <time_frame>At Day 10 post Dose 1</time_frame>
    <description>Seroconversion factor was defined as the fold increase in serum HI GMTs on day 10 compared to day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Factor for Influenza A Subtype H9N2</measure>
    <time_frame>At Day 21 post Dose 1</time_frame>
    <description>Seroconversion factor was defined as the fold increase in serum HI GMTs on day 21 compared to day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects Against H9N2</measure>
    <time_frame>At Day 10 post Dose 1</time_frame>
    <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects Against H9N2</measure>
    <time_frame>At Day 21 post Dose 1</time_frame>
    <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Seroprotection Power Against H9N2</measure>
    <time_frame>At Day 10 post Dose 1</time_frame>
    <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Seroprotection Power Against H9N2</measure>
    <time_frame>At Day 21 post Dose 1</time_frame>
    <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</measure>
    <time_frame>At Day 21 post Dose 2 (Day 42)</time_frame>
    <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</measure>
    <time_frame>At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)</time_frame>
    <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</measure>
    <time_frame>At Day 21 post Dose 2 (Day 42)</time_frame>
    <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer &lt; 1:10 and a post-vaccination titre ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in postvaccination titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</measure>
    <time_frame>At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)</time_frame>
    <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer &lt; 1:10 and a post-vaccination titre ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in post-vaccination titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Factor for Influenza A Subtype H9N2</measure>
    <time_frame>At Day 21 post Dose 2 (Day 42)</time_frame>
    <description>Seroconversion factor defined as the fold increase in serum HI GMTs on day 21 post Dose 3 (Day 42) compared to day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Factor for Influenza A Subtype H9N2</measure>
    <time_frame>At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)</time_frame>
    <description>Seroconversion factor was defined as the fold increase in serum HI GMTs on day 21 post Dose 3 (Day 210 for Subset 1 and Day 386 for Subset 2) compared to day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects Against H9N2</measure>
    <time_frame>At Day 21 post Dose 2 (Day 42)</time_frame>
    <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects Against H9N2</measure>
    <time_frame>At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)</time_frame>
    <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Seroprotection Power Against H9N2</measure>
    <time_frame>At Day 21 post Dose 2 (Day 42)</time_frame>
    <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Seroprotection Power Against H9N2</measure>
    <time_frame>At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)</time_frame>
    <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 30-days (Day 0-30) post vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 0 to Day 51</time_frame>
    <description>A SAE was any untoward medical occurrence which resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, resulted in permanent of serious physical disability or incapacity, caused a congenital anomaly or birth defect in the offspring of a subject or might have put the subject at risk based on medical or scientific judgment or necessitated intervention to prevent such an event (e.q. invasive or malignant cancers, intensive treatment in an emergency room or at home for bronchospasm, blood dyscrasias, or convulsion that do not resulted in hospitalization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Antigen-specific Cluster of Differentiation 4 (CD4) T-cells</measure>
    <time_frame>At Days 0, 10, 21 and 42 post vaccination</time_frame>
    <description>Among expressed immune markers were interferon-gamma (IFN-γ) and cluster of differentiation 40 - ligand (CD40-L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Antigen-specific CD4 T-cells</measure>
    <time_frame>At Days 0, 10, 21 and 42 post-vaccination</time_frame>
    <description>Among expressed immune markers were interleukin-2 (IL-2) and tumour necrosis factor-alpha (TNF-α).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine-positive CD4 T-cells Frequency</measure>
    <time_frame>At Days 10, 21 and 42 post-vaccination</time_frame>
    <description>Among expressed immune markers were interleukin-2 (IL-2), interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 - ligand (CD40-L). Descriptive comparison of the CMI response after Dose 1 and Dose 2 of the monovalent candidate pandemic influenza A vaccine. CMI response was determined in terms of the proportion of lymphocytes (CD4+ and CD8+ per million T cells) activated in vitro by the vaccine antigen on Days 10 and 21 after the Dose 1 and on Day 21 after Dose 2 as compared to Day 0 (pre-vaccination). The results were calculated based on the individual difference between each post-vaccination timepoint (Day 10, Day 21, Day 42) and Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Antigen-specific Cluster of Differentiation 8 (CD8) T-cells</measure>
    <time_frame>At Days 0, 10, 21 and 42 post-vaccination</time_frame>
    <description>Among expressed immune markers were interferon-gamma (IFN-γ) and cluster of differentiation 40 - ligand (CD40-L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Antigen-specific CD8 T-cells</measure>
    <time_frame>At Days 0, 10, 21 and 42 post-vaccination</time_frame>
    <description>Among expressed immune markers were interleukin-2 (IL-2) and tumour necrosis factor-alpha (TNF-α).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine-positive CD8 T-cells Frequency</measure>
    <time_frame>At Days 10, 21 and 42 post-vaccination</time_frame>
    <description>Among expressed immune markers were interleukin-2 (IL-2), interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 - ligand (CD40-L). Descriptive comparison of the CMI response after Dose 1 and Dose 2 of the monovalent candidate pandemic influenza A vaccine. CMI response was determined in terms of the proportion of lymphocytes (CD4+ and CD8+ per million T cells) activated in vitro by the vaccine antigen on Days 10 and 21 after the Dose 1 and on Day 21 after Dose 2 as compared to Day 0 (pre-vaccination). The results were calculated based on the individual difference between each post-vaccination timepoint (Day 10, Day 21, Day 42) and Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms</measure>
    <time_frame>During the 4-days post Dose 1 (Days 0-3), post Dose 2 (Days 21-24) and across these doses</time_frame>
    <description>Assessed solicited local symptoms were pain, redness, swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain which prevents normal everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms</measure>
    <time_frame>During the 4 Days post Dose 3 (Days 189-192 for Subset 1 groups and Days 365-368 for Subset 2 groups)</time_frame>
    <description>Assessed solicited local symptoms were pain, redness, swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain which prevents normal everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms</measure>
    <time_frame>During the 4-days (Day 0-3) post Dose 1</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = axillary temperature higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms</measure>
    <time_frame>During the 4-days post Dose 2 (Days 21-24)</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = axillary temperature higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms</measure>
    <time_frame>During the 4-Days (Day 0-3) across doses 1 and 2</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = axillary temperature higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms</measure>
    <time_frame>During the 4 Days post Dose 3 (Days 189-192 for Subset 1 groups and Days 365-368 for Subset 2 groups)</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axilar temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = fever higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited AEs</measure>
    <time_frame>During the 30-days post Dose 3 (Days 189-219 for Subset 1 groups and Days 365-395 for Subset 2 groups)</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With SAEs</measure>
    <time_frame>Within the 365-day post-vaccination period (Days 0-364 for Subset 1 groups) and within the 395-day post-vaccination period (Days 0-394 for Subset 2 groups)</time_frame>
    <description>A SAE was any untoward medical occurrence which resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, resulted in permanent of serious physical disability or incapacity, caused a congenital anomaly or birth defect in the offspring of a subject or might have put the subject at risk based on medical or scientific judgment or necessitated intervention to prevent such an event (e.q. invasive or malignant cancers, intensive treatment in an emergency room or at home for bronchospasm, blood dyscrasias, or convulsion that do not resulted in hospitalization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any SAEs</measure>
    <time_frame>Up to 30-day post Dose 3 (Days 365-394)</time_frame>
    <description>A SAE was any untoward medical occurrence which resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, resulted in permanent of serious physical disability or incapacity, caused a congenital anomaly or birth defect in the offspring of a subject or might have put the subject at risk based on medical or scientific judgment or necessitated intervention to prevent such an event (e.q. invasive or malignant cancers, intensive treatment in an emergency room or at home for bronchospasm, blood dyscrasias, or convulsion that do not resulted in hospitalization). Only Subset 2 groups had available data for the specified time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Antibody Persistence</measure>
    <time_frame>At Days 189 and 365</time_frame>
    <description>Antibody persistence was evaluated in terms of seroprotection rate (SPR) against influenza A subtype H9N2 and seroconversion rate (SCR) against influenza A subtype H9N2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor (SCF) for Influenza A Subtype H9N2.</measure>
    <time_frame>At Days 189 and 365</time_frame>
    <description>SCF was defined as the fold increase in serum HI GMTs at the post-vaccination time points compared to Day 0, for each vaccine strain.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">385</enrollment>
  <condition>Influenza</condition>
  <condition>Influenza Vaccines</condition>
  <arm_group>
    <arm_group_label>SB218352_15 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB218352_8 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB218352_4 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB218352_2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB218352_8AL Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB218352_4AL Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB218352_2AL Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB218352_15</intervention_name>
    <description>Non-adjuvanted pandemic influenza A formulation 1 vaccine</description>
    <arm_group_label>SB218352_15 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB218352_8</intervention_name>
    <description>Non-adjuvanted pandemic influenza A formulation 2 vaccine</description>
    <arm_group_label>SB218352_8 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB218352_4</intervention_name>
    <description>Non-adjuvanted pandemic influenza A formulation 3 vaccine</description>
    <arm_group_label>SB218352_4 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB218352_2</intervention_name>
    <description>Non-adjuvanted pandemic influenza A formulation 4 vaccine</description>
    <arm_group_label>SB218352_2 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB218352_8AL</intervention_name>
    <description>Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine</description>
    <arm_group_label>SB218352_8AL Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB218352_4AL</intervention_name>
    <description>Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine</description>
    <arm_group_label>SB218352_4AL Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB218352_2AL</intervention_name>
    <description>Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine</description>
    <arm_group_label>SB218352_2AL Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol

          -  A male or female aged over 60 years at the time of vaccination.

          -  Written informed consent obtained from the subject.

        Exclusion criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the administration of the study vaccine, or
             planned use during the study period.

          -  Participation in an earlier study with a candidate pandemic H9N2 vaccine.

          -  Acute disease at the time of enrolment.

          -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional
             abnormality

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Drug and/or alcohol dependency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Finsterwalde</city>
        <state>Brandenburg</state>
        <zip>03238</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ketzin</city>
        <state>Brandenburg</state>
        <zip>14669</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tostedt</city>
        <state>Niedersachsen</state>
        <zip>21255</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geringswalde</city>
        <state>Sachsen</state>
        <zip>09326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schmiedeberg</city>
        <state>Sachsen</state>
        <zip>01762</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Bramstedt</city>
        <state>Schleswig-Holstein</state>
        <zip>24576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig-Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elmshorn</city>
        <state>Schleswig-Holstein</state>
        <zip>25335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>March 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2006</study_first_posted>
  <results_first_submitted>September 22, 2017</results_first_submitted>
  <results_first_submitted_qc>February 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prophylaxis of pandemic influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>102499</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102499</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102499</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102499</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>102499</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>After Part I, the core study (study period from Visit 1 on Day 0 up to the phone contact on Day 51), the enrolled subjects were stratified into Subset 1 (Part II – Visit 5 on Day 189 to study conclusion, i.e ., Visit 7 on Day 365) or Subset 2 (Part II – Visit 6 on Day 365 to study conclusion, i.e ., phone contact on Day 395).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SB218352_15 Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="P2">
          <title>SB218352_8 Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="P3">
          <title>SB218352_4 Group:</title>
          <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="P4">
          <title>SB218352_2 Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="P5">
          <title>SB218352_8AL Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="P6">
          <title>SB218352_4AL Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="P7">
          <title>SB218352_2AL Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Da y 189 for subjects in Subs t I and at Day 0, Day 21 and Da y 365 for subjects in Subset 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Part I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="55"/>
                <participants group_id="P6" count="55"/>
                <participants group_id="P7" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="55"/>
                <participants group_id="P6" count="55"/>
                <participants group_id="P7" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Part II for Subset 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Study Part II for Subset 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SB218352_15 Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="B2">
          <title>SB218352_8 Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="B3">
          <title>SB218352_4 Group:</title>
          <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="B4">
          <title>SB218352_2 Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="B5">
          <title>SB218352_8AL Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="B6">
          <title>SB218352_4AL Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="B7">
          <title>SB218352_2AL Group:</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Da y 189 for subjects in Subs t I and at Day 0, Day 21 and Da y 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="55"/>
            <count group_id="B6" value="55"/>
            <count group_id="B7" value="55"/>
            <count group_id="B8" value="385"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.4" spread="5.11"/>
                    <measurement group_id="B2" value="69.0" spread="5.66"/>
                    <measurement group_id="B3" value="69.2" spread="5.77"/>
                    <measurement group_id="B4" value="69.1" spread="5.94"/>
                    <measurement group_id="B5" value="68.4" spread="5.92"/>
                    <measurement group_id="B6" value="68.4" spread="6.31"/>
                    <measurement group_id="B7" value="69.8" spread="5.91"/>
                    <measurement group_id="B8" value="68.9" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="41"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="33"/>
                    <measurement group_id="B8" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Arabic/North African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White-Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="55"/>
                    <measurement group_id="B7" value="55"/>
                    <measurement group_id="B8" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</title>
        <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
        <time_frame>At Day 10 post Dose 1</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</title>
          <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="17.1" upper_limit="35.0"/>
                    <measurement group_id="O2" value="15.6" lower_limit="11.0" upper_limit="22.1"/>
                    <measurement group_id="O3" value="14.6" lower_limit="10.2" upper_limit="20.8"/>
                    <measurement group_id="O4" value="9.8" lower_limit="7.5" upper_limit="12.8"/>
                    <measurement group_id="O5" value="23.3" lower_limit="16.9" upper_limit="32.0"/>
                    <measurement group_id="O6" value="18.8" lower_limit="12.3" upper_limit="28.5"/>
                    <measurement group_id="O7" value="16.9" lower_limit="12.3" upper_limit="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</title>
        <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
        <time_frame>At Day 21 post Dose 1</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</title>
          <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" lower_limit="22.1" upper_limit="47.8"/>
                    <measurement group_id="O2" value="20.1" lower_limit="14.0" upper_limit="28.9"/>
                    <measurement group_id="O3" value="21.9" lower_limit="13.8" upper_limit="34.8"/>
                    <measurement group_id="O4" value="12.0" lower_limit="9.1" upper_limit="15.9"/>
                    <measurement group_id="O5" value="42.1" lower_limit="28.7" upper_limit="61.7"/>
                    <measurement group_id="O6" value="20.0" lower_limit="13.3" upper_limit="30.0"/>
                    <measurement group_id="O7" value="17.8" lower_limit="12.9" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</title>
        <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer lower than (&lt;) 1:10 and a post-vaccination titre higher than or equal to (≥) 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in post-vaccination titer</description>
        <time_frame>At Day 10 post Dose 1</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</title>
          <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer lower than (&lt;) 1:10 and a post-vaccination titre higher than or equal to (≥) 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in post-vaccination titer</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</title>
        <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer &lt; 1:10 and a post-vaccination titre ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in post-vaccination titer</description>
        <time_frame>At Day 21 post Dose 1</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</title>
          <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer &lt; 1:10 and a post-vaccination titre ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in post-vaccination titer</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Factor for Influenza A Subtype H9N2</title>
        <description>Seroconversion factor was defined as the fold increase in serum HI GMTs on day 10 compared to day 0.</description>
        <time_frame>At Day 10 post Dose 1</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Influenza A Subtype H9N2</title>
          <description>Seroconversion factor was defined as the fold increase in serum HI GMTs on day 10 compared to day 0.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.9" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.5" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.4" upper_limit="2.9"/>
                    <measurement group_id="O4" value="1.4" lower_limit="1.2" upper_limit="1.7"/>
                    <measurement group_id="O5" value="3.1" lower_limit="2.3" upper_limit="4.2"/>
                    <measurement group_id="O6" value="2.4" lower_limit="1.6" upper_limit="3.7"/>
                    <measurement group_id="O7" value="2.4" lower_limit="1.7" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Factor for Influenza A Subtype H9N2</title>
        <description>Seroconversion factor was defined as the fold increase in serum HI GMTs on day 21 compared to day 0.</description>
        <time_frame>At Day 21 post Dose 1</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Influenza A Subtype H9N2</title>
          <description>Seroconversion factor was defined as the fold increase in serum HI GMTs on day 21 compared to day 0.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="2.3" upper_limit="5.7"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.8" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.8" upper_limit="5.0"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.4" upper_limit="2.2"/>
                    <measurement group_id="O5" value="5.5" lower_limit="3.7" upper_limit="8.4"/>
                    <measurement group_id="O6" value="2.6" lower_limit="1.7" upper_limit="3.9"/>
                    <measurement group_id="O7" value="2.5" lower_limit="1.8" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects Against H9N2</title>
        <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
        <time_frame>At Day 10 post Dose 1</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against H9N2</title>
          <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects Against H9N2</title>
        <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
        <time_frame>At Day 21 post Dose 1</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against H9N2</title>
          <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Seroprotection Power Against H9N2</title>
        <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
        <time_frame>At Day 10 post Dose 1</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Seroprotection Power Against H9N2</title>
          <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="22"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="18"/>
                <count group_id="O12" value="20"/>
                <count group_id="O13" value="24"/>
                <count group_id="O14" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="10"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Seroprotection Power Against H9N2</title>
        <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
        <time_frame>At Day 21 post Dose 1</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Seroprotection Power Against H9N2</title>
          <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="22"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="18"/>
                <count group_id="O12" value="20"/>
                <count group_id="O13" value="24"/>
                <count group_id="O14" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="12"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
        <time_frame>During the 30-days (Day 0-30) post vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVc), which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVc), which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>A SAE was any untoward medical occurrence which resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, resulted in permanent of serious physical disability or incapacity, caused a congenital anomaly or birth defect in the offspring of a subject or might have put the subject at risk based on medical or scientific judgment or necessitated intervention to prevent such an event (e.q. invasive or malignant cancers, intensive treatment in an emergency room or at home for bronchospasm, blood dyscrasias, or convulsion that do not resulted in hospitalization).</description>
        <time_frame>From Day 0 to Day 51</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVc), which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>A SAE was any untoward medical occurrence which resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, resulted in permanent of serious physical disability or incapacity, caused a congenital anomaly or birth defect in the offspring of a subject or might have put the subject at risk based on medical or scientific judgment or necessitated intervention to prevent such an event (e.q. invasive or malignant cancers, intensive treatment in an emergency room or at home for bronchospasm, blood dyscrasias, or convulsion that do not resulted in hospitalization).</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVc), which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Antigen-specific Cluster of Differentiation 4 (CD4) T-cells</title>
        <description>Among expressed immune markers were interferon-gamma (IFN-γ) and cluster of differentiation 40 - ligand (CD40-L).</description>
        <time_frame>At Days 0, 10, 21 and 42 post vaccination</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Antigen-specific Cluster of Differentiation 4 (CD4) T-cells</title>
          <description>Among expressed immune markers were interferon-gamma (IFN-γ) and cluster of differentiation 40 - ligand (CD40-L).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>T-cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4-ALL DOUBLES, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="557.00" lower_limit="509.00" upper_limit="827.00"/>
                    <measurement group_id="O2" value="785.00" lower_limit="489.00" upper_limit="1072.00"/>
                    <measurement group_id="O3" value="782.00" lower_limit="441.00" upper_limit="1052.00"/>
                    <measurement group_id="O4" value="472.00" lower_limit="305.00" upper_limit="1025.00"/>
                    <measurement group_id="O5" value="738.00" lower_limit="558.00" upper_limit="1284.00"/>
                    <measurement group_id="O6" value="691.00" lower_limit="547.00" upper_limit="873.00"/>
                    <measurement group_id="O7" value="594.50" lower_limit="453.50" upper_limit="1020.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-ALL DOUBLES, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="21"/>
                    <count group_id="O7" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1049.00" lower_limit="779.00" upper_limit="1753.00"/>
                    <measurement group_id="O2" value="1148.00" lower_limit="702.00" upper_limit="1891.00"/>
                    <measurement group_id="O3" value="1066.50" lower_limit="647.00" upper_limit="1809.00"/>
                    <measurement group_id="O4" value="844.00" lower_limit="478.00" upper_limit="1548.00"/>
                    <measurement group_id="O5" value="1275.00" lower_limit="884.00" upper_limit="1691.00"/>
                    <measurement group_id="O6" value="1194.00" lower_limit="760.00" upper_limit="1453.00"/>
                    <measurement group_id="O7" value="874.00" lower_limit="626.00" upper_limit="1399.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-ALL DOUBLES, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1118.00" lower_limit="904.00" upper_limit="1424.00"/>
                    <measurement group_id="O2" value="1396.00" lower_limit="923.00" upper_limit="1962.00"/>
                    <measurement group_id="O3" value="1212.00" lower_limit="784.00" upper_limit="1822.00"/>
                    <measurement group_id="O4" value="791.50" lower_limit="390.00" upper_limit="1229.00"/>
                    <measurement group_id="O5" value="1555.00" lower_limit="1073.00" upper_limit="1873.00"/>
                    <measurement group_id="O6" value="989.50" lower_limit="734.00" upper_limit="1912.50"/>
                    <measurement group_id="O7" value="972.50" lower_limit="820.00" upper_limit="1466.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-ALL DOUBLES, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100.00" lower_limit="733.00" upper_limit="1567.00"/>
                    <measurement group_id="O2" value="1349.00" lower_limit="722.00" upper_limit="1812.00"/>
                    <measurement group_id="O3" value="967.00" lower_limit="647.00" upper_limit="1693.00"/>
                    <measurement group_id="O4" value="965.00" lower_limit="651.00" upper_limit="1645.00"/>
                    <measurement group_id="O5" value="1600.00" lower_limit="936.00" upper_limit="2156.00"/>
                    <measurement group_id="O6" value="1198.00" lower_limit="791.50" upper_limit="1646.50"/>
                    <measurement group_id="O7" value="1059.50" lower_limit="894.00" upper_limit="1636.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-CD40L, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="583.00" lower_limit="471.00" upper_limit="810.00"/>
                    <measurement group_id="O2" value="574.00" lower_limit="467.00" upper_limit="1095.00"/>
                    <measurement group_id="O3" value="750.00" lower_limit="441.00" upper_limit="1028.00"/>
                    <measurement group_id="O4" value="438.00" lower_limit="308.00" upper_limit="920.00"/>
                    <measurement group_id="O5" value="720.00" lower_limit="442.00" upper_limit="1263.00"/>
                    <measurement group_id="O6" value="714.00" lower_limit="368.00" upper_limit="866.00"/>
                    <measurement group_id="O7" value="600.00" lower_limit="449.00" upper_limit="976.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-CD40L, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="21"/>
                    <count group_id="O7" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1028.00" lower_limit="779.00" upper_limit="1446.00"/>
                    <measurement group_id="O2" value="1148.00" lower_limit="668.00" upper_limit="1922.00"/>
                    <measurement group_id="O3" value="981.00" lower_limit="626.00" upper_limit="1654.00"/>
                    <measurement group_id="O4" value="769.00" lower_limit="478.00" upper_limit="1552.00"/>
                    <measurement group_id="O5" value="1161.00" lower_limit="630.00" upper_limit="1639.00"/>
                    <measurement group_id="O6" value="1158.00" lower_limit="760.00" upper_limit="1378.00"/>
                    <measurement group_id="O7" value="886.00" lower_limit="613.00" upper_limit="1399.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-CD40L, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1069.00" lower_limit="851.00" upper_limit="1320.00"/>
                    <measurement group_id="O2" value="1243.50" lower_limit="730.00" upper_limit="1511.00"/>
                    <measurement group_id="O3" value="1074.00" lower_limit="752.00" upper_limit="1483.00"/>
                    <measurement group_id="O4" value="788.50" lower_limit="376.00" upper_limit="1229.00"/>
                    <measurement group_id="O5" value="1536.00" lower_limit="884.00" upper_limit="1820.00"/>
                    <measurement group_id="O6" value="974.50" lower_limit="710.00" upper_limit="1790.00"/>
                    <measurement group_id="O7" value="900.50" lower_limit="753.00" upper_limit="1421.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-CD40L, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1037.00" lower_limit="721.00" upper_limit="1545.00"/>
                    <measurement group_id="O2" value="1088.00" lower_limit="649.00" upper_limit="1748.00"/>
                    <measurement group_id="O3" value="945.00" lower_limit="641.00" upper_limit="1644.00"/>
                    <measurement group_id="O4" value="999.00" lower_limit="651.00" upper_limit="1645.00"/>
                    <measurement group_id="O5" value="1492.50" lower_limit="836.00" upper_limit="2147.50"/>
                    <measurement group_id="O6" value="1177.50" lower_limit="746.50" upper_limit="1608.50"/>
                    <measurement group_id="O7" value="984.00" lower_limit="824.00" upper_limit="1636.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IFN-γ, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278.00" lower_limit="120.00" upper_limit="353.00"/>
                    <measurement group_id="O2" value="233.00" lower_limit="109.00" upper_limit="761.00"/>
                    <measurement group_id="O3" value="198.00" lower_limit="172.00" upper_limit="395.00"/>
                    <measurement group_id="O4" value="160.00" lower_limit="80.00" upper_limit="280.00"/>
                    <measurement group_id="O5" value="299.00" lower_limit="125.00" upper_limit="434.00"/>
                    <measurement group_id="O6" value="212.50" lower_limit="177.00" upper_limit="464.00"/>
                    <measurement group_id="O7" value="217.50" lower_limit="149.00" upper_limit="295.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IFN-γ, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="21"/>
                    <count group_id="O7" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466.00" lower_limit="273.00" upper_limit="612.00"/>
                    <measurement group_id="O2" value="457.00" lower_limit="196.00" upper_limit="539.00"/>
                    <measurement group_id="O3" value="582.50" lower_limit="336.00" upper_limit="693.00"/>
                    <measurement group_id="O4" value="365.00" lower_limit="93.00" upper_limit="674.00"/>
                    <measurement group_id="O5" value="463.00" lower_limit="239.00" upper_limit="926.00"/>
                    <measurement group_id="O6" value="400.00" lower_limit="170.00" upper_limit="581.00"/>
                    <measurement group_id="O7" value="245.00" lower_limit="196.00" upper_limit="425.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IFN-γ, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411.00" lower_limit="231.00" upper_limit="638.00"/>
                    <measurement group_id="O2" value="482.00" lower_limit="253.00" upper_limit="651.00"/>
                    <measurement group_id="O3" value="516.00" lower_limit="291.00" upper_limit="629.00"/>
                    <measurement group_id="O4" value="228.50" lower_limit="171.00" upper_limit="558.00"/>
                    <measurement group_id="O5" value="484.00" lower_limit="305.00" upper_limit="784.00"/>
                    <measurement group_id="O6" value="391.00" lower_limit="204.00" upper_limit="911.50"/>
                    <measurement group_id="O7" value="412.00" lower_limit="298.00" upper_limit="654.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IFN-γ, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342.00" lower_limit="234.00" upper_limit="449.00"/>
                    <measurement group_id="O2" value="332.00" lower_limit="245.00" upper_limit="739.00"/>
                    <measurement group_id="O3" value="346.00" lower_limit="232.00" upper_limit="549.00"/>
                    <measurement group_id="O4" value="344.00" lower_limit="211.00" upper_limit="632.00"/>
                    <measurement group_id="O5" value="669.50" lower_limit="312.50" upper_limit="915.50"/>
                    <measurement group_id="O6" value="445.00" lower_limit="361.50" upper_limit="790.00"/>
                    <measurement group_id="O7" value="483.00" lower_limit="232.00" upper_limit="733.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Antigen-specific CD4 T-cells</title>
        <description>Among expressed immune markers were interleukin-2 (IL-2) and tumour necrosis factor-alpha (TNF-α).</description>
        <time_frame>At Days 0, 10, 21 and 42 post-vaccination</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Antigen-specific CD4 T-cells</title>
          <description>Among expressed immune markers were interleukin-2 (IL-2) and tumour necrosis factor-alpha (TNF-α).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>T-cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4-IL-2, DAY 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414.00" lower_limit="322.00" upper_limit="661.00"/>
                    <measurement group_id="O2" value="491.00" lower_limit="356.00" upper_limit="922.00"/>
                    <measurement group_id="O3" value="524.00" lower_limit="351.00" upper_limit="801.00"/>
                    <measurement group_id="O4" value="381.00" lower_limit="208.00" upper_limit="559.00"/>
                    <measurement group_id="O5" value="509.00" lower_limit="377.00" upper_limit="987.00"/>
                    <measurement group_id="O6" value="487.50" lower_limit="269.00" upper_limit="579.00"/>
                    <measurement group_id="O7" value="437.00" lower_limit="320.00" upper_limit="641.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IL-2, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="21"/>
                    <count group_id="O7" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="751.00" lower_limit="582.00" upper_limit="1234.00"/>
                    <measurement group_id="O2" value="985.00" lower_limit="581.00" upper_limit="1423.00"/>
                    <measurement group_id="O3" value="814.00" lower_limit="460.00" upper_limit="1271.00"/>
                    <measurement group_id="O4" value="579.00" lower_limit="264.00" upper_limit="1106.00"/>
                    <measurement group_id="O5" value="924.00" lower_limit="619.00" upper_limit="1284.00"/>
                    <measurement group_id="O6" value="821.00" lower_limit="616.00" upper_limit="1155.00"/>
                    <measurement group_id="O7" value="622.00" lower_limit="392.00" upper_limit="981.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IL-2, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="888.00" lower_limit="557.00" upper_limit="1221.00"/>
                    <measurement group_id="O2" value="1013.50" lower_limit="819.00" upper_limit="1790.00"/>
                    <measurement group_id="O3" value="814.00" lower_limit="569.00" upper_limit="1281.00"/>
                    <measurement group_id="O4" value="625.00" lower_limit="227.00" upper_limit="865.00"/>
                    <measurement group_id="O5" value="988.00" lower_limit="763.00" upper_limit="1697.00"/>
                    <measurement group_id="O6" value="799.00" lower_limit="640.00" upper_limit="1405.50"/>
                    <measurement group_id="O7" value="764.00" lower_limit="632.00" upper_limit="1070.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IL-2, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="913.00" lower_limit="561.00" upper_limit="1334.00"/>
                    <measurement group_id="O2" value="876.00" lower_limit="562.00" upper_limit="1529.00"/>
                    <measurement group_id="O3" value="714.00" lower_limit="559.00" upper_limit="1322.00"/>
                    <measurement group_id="O4" value="761.00" lower_limit="534.00" upper_limit="1224.00"/>
                    <measurement group_id="O5" value="1233.50" lower_limit="707.50" upper_limit="1743.50"/>
                    <measurement group_id="O6" value="953.00" lower_limit="658.50" upper_limit="1331.00"/>
                    <measurement group_id="O7" value="890.00" lower_limit="583.00" upper_limit="1216.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-TNF-α, DAY 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.00" lower_limit="273.00" upper_limit="669.00"/>
                    <measurement group_id="O2" value="470.00" lower_limit="287.00" upper_limit="999.00"/>
                    <measurement group_id="O3" value="495.00" lower_limit="321.00" upper_limit="676.00"/>
                    <measurement group_id="O4" value="337.00" lower_limit="240.00" upper_limit="705.00"/>
                    <measurement group_id="O5" value="538.00" lower_limit="327.00" upper_limit="759.00"/>
                    <measurement group_id="O6" value="495.50" lower_limit="348.00" upper_limit="669.00"/>
                    <measurement group_id="O7" value="395.00" lower_limit="282.00" upper_limit="680.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-TNF-α, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="21"/>
                    <count group_id="O7" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="817.00" lower_limit="665.00" upper_limit="1229.00"/>
                    <measurement group_id="O2" value="822.00" lower_limit="491.00" upper_limit="1141.00"/>
                    <measurement group_id="O3" value="717.00" lower_limit="347.00" upper_limit="1062.00"/>
                    <measurement group_id="O4" value="522.00" lower_limit="376.00" upper_limit="1073.00"/>
                    <measurement group_id="O5" value="728.00" lower_limit="534.00" upper_limit="1126.00"/>
                    <measurement group_id="O6" value="793.00" lower_limit="637.00" upper_limit="875.00"/>
                    <measurement group_id="O7" value="641.00" lower_limit="414.00" upper_limit="929.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-TNF-α, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="923.00" lower_limit="637.00" upper_limit="1207.00"/>
                    <measurement group_id="O2" value="842.50" lower_limit="676.00" upper_limit="1303.00"/>
                    <measurement group_id="O3" value="870.00" lower_limit="519.00" upper_limit="1252.00"/>
                    <measurement group_id="O4" value="491.50" lower_limit="359.00" upper_limit="837.00"/>
                    <measurement group_id="O5" value="1244.00" lower_limit="749.00" upper_limit="1455.00"/>
                    <measurement group_id="O6" value="650.50" lower_limit="458.50" upper_limit="1307.50"/>
                    <measurement group_id="O7" value="672.50" lower_limit="557.00" upper_limit="1150.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-TNF-α, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="868.00" lower_limit="530.00" upper_limit="1163.00"/>
                    <measurement group_id="O2" value="899.00" lower_limit="505.00" upper_limit="1436.00"/>
                    <measurement group_id="O3" value="608.00" lower_limit="464.00" upper_limit="994.00"/>
                    <measurement group_id="O4" value="717.00" lower_limit="368.00" upper_limit="1261.00"/>
                    <measurement group_id="O5" value="1079.50" lower_limit="696.50" upper_limit="1621.00"/>
                    <measurement group_id="O6" value="829.00" lower_limit="592.50" upper_limit="1128.50"/>
                    <measurement group_id="O7" value="722.00" lower_limit="520.00" upper_limit="988.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cytokine-positive CD4 T-cells Frequency</title>
        <description>Among expressed immune markers were interleukin-2 (IL-2), interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 - ligand (CD40-L). Descriptive comparison of the CMI response after Dose 1 and Dose 2 of the monovalent candidate pandemic influenza A vaccine. CMI response was determined in terms of the proportion of lymphocytes (CD4+ and CD8+ per million T cells) activated in vitro by the vaccine antigen on Days 10 and 21 after the Dose 1 and on Day 21 after Dose 2 as compared to Day 0 (pre-vaccination). The results were calculated based on the individual difference between each post-vaccination timepoint (Day 10, Day 21, Day 42) and Day 0.</description>
        <time_frame>At Days 10, 21 and 42 post-vaccination</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cytokine-positive CD4 T-cells Frequency</title>
          <description>Among expressed immune markers were interleukin-2 (IL-2), interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 - ligand (CD40-L). Descriptive comparison of the CMI response after Dose 1 and Dose 2 of the monovalent candidate pandemic influenza A vaccine. CMI response was determined in terms of the proportion of lymphocytes (CD4+ and CD8+ per million T cells) activated in vitro by the vaccine antigen on Days 10 and 21 after the Dose 1 and on Day 21 after Dose 2 as compared to Day 0 (pre-vaccination). The results were calculated based on the individual difference between each post-vaccination timepoint (Day 10, Day 21, Day 42) and Day 0.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>CD4+ T-cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4-ALL DOUBLES, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295.00" lower_limit="9.00" upper_limit="859.00"/>
                    <measurement group_id="O2" value="326.00" lower_limit="127.50" upper_limit="731.00"/>
                    <measurement group_id="O3" value="219.00" lower_limit="-64.00" upper_limit="767.00"/>
                    <measurement group_id="O4" value="342.00" lower_limit="-58.00" upper_limit="657.00"/>
                    <measurement group_id="O5" value="434.50" lower_limit="24.00" upper_limit="796.50"/>
                    <measurement group_id="O6" value="398.00" lower_limit="11.00" upper_limit="773.00"/>
                    <measurement group_id="O7" value="139.00" lower_limit="-69.50" upper_limit="981.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-ALL DOUBLES, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.00" lower_limit="108.00" upper_limit="539.00"/>
                    <measurement group_id="O2" value="477.00" lower_limit="280.50" upper_limit="766.00"/>
                    <measurement group_id="O3" value="359.00" lower_limit="-114.00" upper_limit="780.00"/>
                    <measurement group_id="O4" value="252.50" lower_limit="-62.00" upper_limit="669.00"/>
                    <measurement group_id="O5" value="645.00" lower_limit="274.00" upper_limit="1037.00"/>
                    <measurement group_id="O6" value="440.50" lower_limit="177.00" upper_limit="1195.00"/>
                    <measurement group_id="O7" value="283.00" lower_limit="98.00" upper_limit="660.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-ALL DOUBLES, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384.00" lower_limit="116.00" upper_limit="678.00"/>
                    <measurement group_id="O2" value="360.00" lower_limit="-120.00" upper_limit="766.00"/>
                    <measurement group_id="O3" value="482.50" lower_limit="-3.00" upper_limit="791.00"/>
                    <measurement group_id="O4" value="441.00" lower_limit="298.00" upper_limit="708.00"/>
                    <measurement group_id="O5" value="689.00" lower_limit="9.00" upper_limit="1104.00"/>
                    <measurement group_id="O6" value="554.00" lower_limit="353.00" upper_limit="751.00"/>
                    <measurement group_id="O7" value="445.50" lower_limit="252.50" upper_limit="786.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-CD40L, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.00" lower_limit="-18.00" upper_limit="859.00"/>
                    <measurement group_id="O2" value="299.50" lower_limit="20.50" upper_limit="680.50"/>
                    <measurement group_id="O3" value="149.50" lower_limit="-98.50" upper_limit="686.50"/>
                    <measurement group_id="O4" value="303.50" lower_limit="-28.00" upper_limit="650.00"/>
                    <measurement group_id="O5" value="384.50" lower_limit="10.50" upper_limit="745.50"/>
                    <measurement group_id="O6" value="335.00" lower_limit="-9.00" upper_limit="741.00"/>
                    <measurement group_id="O7" value="104.50" lower_limit="-37.00" upper_limit="930.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-CD40L, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.00" lower_limit="4.00" upper_limit="481.00"/>
                    <measurement group_id="O2" value="429.50" lower_limit="142.00" upper_limit="623.00"/>
                    <measurement group_id="O3" value="271.00" lower_limit="-114.00" upper_limit="735.00"/>
                    <measurement group_id="O4" value="237.00" lower_limit="-42.50" upper_limit="639.50"/>
                    <measurement group_id="O5" value="630.00" lower_limit="48.00" upper_limit="996.00"/>
                    <measurement group_id="O6" value="433.00" lower_limit="158.00" upper_limit="1095.00"/>
                    <measurement group_id="O7" value="286.00" lower_limit="70.00" upper_limit="547.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-CD40L, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.00" lower_limit="62.00" upper_limit="687.00"/>
                    <measurement group_id="O2" value="320.00" lower_limit="-14.00" upper_limit="737.00"/>
                    <measurement group_id="O3" value="440.00" lower_limit="-88.00" upper_limit="691.00"/>
                    <measurement group_id="O4" value="451.00" lower_limit="310.00" upper_limit="751.00"/>
                    <measurement group_id="O5" value="685.00" lower_limit="-3.00" upper_limit="1071.00"/>
                    <measurement group_id="O6" value="513.00" lower_limit="336.00" upper_limit="725.00"/>
                    <measurement group_id="O7" value="445.00" lower_limit="232.50" upper_limit="765.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IFN-γ, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.00" lower_limit="-17.00" upper_limit="200.00"/>
                    <measurement group_id="O2" value="134.50" lower_limit="-108.00" upper_limit="451.50"/>
                    <measurement group_id="O3" value="172.50" lower_limit="3.50" upper_limit="478.00"/>
                    <measurement group_id="O4" value="78.50" lower_limit="0.00" upper_limit="438.00"/>
                    <measurement group_id="O5" value="167.00" lower_limit="92.00" upper_limit="427.00"/>
                    <measurement group_id="O6" value="165.00" lower_limit="23.00" upper_limit="273.00"/>
                    <measurement group_id="O7" value="72.50" lower_limit="-54.50" upper_limit="375.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IFN-γ, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.00" lower_limit="-58.00" upper_limit="256.00"/>
                    <measurement group_id="O2" value="120.00" lower_limit="-34.00" upper_limit="442.00"/>
                    <measurement group_id="O3" value="205.00" lower_limit="-3.00" upper_limit="343.00"/>
                    <measurement group_id="O4" value="77.50" lower_limit="-41.00" upper_limit="304.00"/>
                    <measurement group_id="O5" value="145.50" lower_limit="57.00" upper_limit="506.00"/>
                    <measurement group_id="O6" value="229.00" lower_limit="-57.00" upper_limit="600.00"/>
                    <measurement group_id="O7" value="150.00" lower_limit="83.00" upper_limit="260.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IFN-γ, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.00" lower_limit="27.00" upper_limit="196.00"/>
                    <measurement group_id="O2" value="145.00" lower_limit="-115.00" upper_limit="236.00"/>
                    <measurement group_id="O3" value="124.00" lower_limit="8.50" upper_limit="350.50"/>
                    <measurement group_id="O4" value="136.00" lower_limit="60.00" upper_limit="248.00"/>
                    <measurement group_id="O5" value="320.00" lower_limit="-19.00" upper_limit="621.00"/>
                    <measurement group_id="O6" value="186.00" lower_limit="103.00" upper_limit="375.00"/>
                    <measurement group_id="O7" value="233.50" lower_limit="64.50" upper_limit="544.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IL-2, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.00" lower_limit="51.00" upper_limit="574.00"/>
                    <measurement group_id="O2" value="289.50" lower_limit="48.00" upper_limit="729.50"/>
                    <measurement group_id="O3" value="152.00" lower_limit="-45.50" upper_limit="648.50"/>
                    <measurement group_id="O4" value="225.00" lower_limit="0.00" upper_limit="442.00"/>
                    <measurement group_id="O5" value="369.50" lower_limit="-38.00" upper_limit="645.00"/>
                    <measurement group_id="O6" value="242.00" lower_limit="120.00" upper_limit="668.00"/>
                    <measurement group_id="O7" value="158.50" lower_limit="-90.00" upper_limit="523.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IL2, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227.00" lower_limit="48.00" upper_limit="547.00"/>
                    <measurement group_id="O2" value="401.00" lower_limit="170.50" upper_limit="644.00"/>
                    <measurement group_id="O3" value="297.00" lower_limit="15.00" upper_limit="549.00"/>
                    <measurement group_id="O4" value="117.00" lower_limit="-64.50" upper_limit="459.00"/>
                    <measurement group_id="O5" value="400.50" lower_limit="132.00" upper_limit="789.00"/>
                    <measurement group_id="O6" value="518.00" lower_limit="224.00" upper_limit="701.00"/>
                    <measurement group_id="O7" value="257.00" lower_limit="150.00" upper_limit="499.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-IL-2, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.50" lower_limit="57.00" upper_limit="613.00"/>
                    <measurement group_id="O2" value="285.00" lower_limit="58.00" upper_limit="540.00"/>
                    <measurement group_id="O3" value="294.50" lower_limit="158.00" upper_limit="457.50"/>
                    <measurement group_id="O4" value="359.00" lower_limit="180.00" upper_limit="656.00"/>
                    <measurement group_id="O5" value="648.00" lower_limit="40.00" upper_limit="970.00"/>
                    <measurement group_id="O6" value="523.00" lower_limit="381.00" upper_limit="629.00"/>
                    <measurement group_id="O7" value="493.00" lower_limit="198.00" upper_limit="766.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-TNF-α, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324.00" lower_limit="50.00" upper_limit="425.00"/>
                    <measurement group_id="O2" value="221.50" lower_limit="41.00" upper_limit="608.50"/>
                    <measurement group_id="O3" value="194.00" lower_limit="70.50" upper_limit="550.00"/>
                    <measurement group_id="O4" value="122.00" lower_limit="-68.00" upper_limit="501.00"/>
                    <measurement group_id="O5" value="210.50" lower_limit="-61.00" upper_limit="423.00"/>
                    <measurement group_id="O6" value="194.00" lower_limit="-33.00" upper_limit="469.00"/>
                    <measurement group_id="O7" value="140.50" lower_limit="-42.00" upper_limit="540.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-TNF-α, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.00" lower_limit="150.00" upper_limit="412.00"/>
                    <measurement group_id="O2" value="282.50" lower_limit="164.00" upper_limit="610.50"/>
                    <measurement group_id="O3" value="259.00" lower_limit="12.00" upper_limit="648.00"/>
                    <measurement group_id="O4" value="142.50" lower_limit="-17.00" upper_limit="430.00"/>
                    <measurement group_id="O5" value="470.50" lower_limit="233.00" upper_limit="795.00"/>
                    <measurement group_id="O6" value="156.50" lower_limit="31.00" upper_limit="937.00"/>
                    <measurement group_id="O7" value="229.00" lower_limit="139.00" upper_limit="340.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-TNF-α, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.50" lower_limit="177.00" upper_limit="693.00"/>
                    <measurement group_id="O2" value="157.00" lower_limit="-46.00" upper_limit="538.00"/>
                    <measurement group_id="O3" value="175.00" lower_limit="-20.50" upper_limit="510.50"/>
                    <measurement group_id="O4" value="239.00" lower_limit="114.00" upper_limit="574.00"/>
                    <measurement group_id="O5" value="454.00" lower_limit="234.00" upper_limit="805.00"/>
                    <measurement group_id="O6" value="313.00" lower_limit="239.00" upper_limit="484.00"/>
                    <measurement group_id="O7" value="252.50" lower_limit="106.00" upper_limit="606.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Antigen-specific Cluster of Differentiation 8 (CD8) T-cells</title>
        <description>Among expressed immune markers were interferon-gamma (IFN-γ) and cluster of differentiation 40 - ligand (CD40-L).</description>
        <time_frame>At Days 0, 10, 21 and 42 post-vaccination</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Antigen-specific Cluster of Differentiation 8 (CD8) T-cells</title>
          <description>Among expressed immune markers were interferon-gamma (IFN-γ) and cluster of differentiation 40 - ligand (CD40-L).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>CD8+ T-cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD8-ALL DOUBLES, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.00" lower_limit="1.00" upper_limit="168.00"/>
                    <measurement group_id="O2" value="62.00" lower_limit="1.00" upper_limit="186.00"/>
                    <measurement group_id="O3" value="104.00" lower_limit="27.00" upper_limit="292.00"/>
                    <measurement group_id="O4" value="83.50" lower_limit="1.00" upper_limit="294.00"/>
                    <measurement group_id="O5" value="83.00" lower_limit="1.00" upper_limit="302.00"/>
                    <measurement group_id="O6" value="83.00" lower_limit="1.00" upper_limit="263.00"/>
                    <measurement group_id="O7" value="12.00" lower_limit="1.00" upper_limit="124.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-ALL DOUBLES, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.50" lower_limit="1.00" upper_limit="320.00"/>
                    <measurement group_id="O2" value="47.50" lower_limit="1.00" upper_limit="195.00"/>
                    <measurement group_id="O3" value="148.00" lower_limit="2.00" upper_limit="218.00"/>
                    <measurement group_id="O4" value="102.00" lower_limit="1.00" upper_limit="235.00"/>
                    <measurement group_id="O5" value="34.00" lower_limit="1.00" upper_limit="313.00"/>
                    <measurement group_id="O6" value="73.00" lower_limit="9.00" upper_limit="347.00"/>
                    <measurement group_id="O7" value="17.50" lower_limit="1.00" upper_limit="175.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-ALL DOUBLES, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.00" lower_limit="1.00" upper_limit="187.50"/>
                    <measurement group_id="O2" value="19.00" lower_limit="1.00" upper_limit="151.00"/>
                    <measurement group_id="O3" value="57.00" lower_limit="1.00" upper_limit="361.00"/>
                    <measurement group_id="O4" value="51.00" lower_limit="1.00" upper_limit="378.00"/>
                    <measurement group_id="O5" value="172.00" lower_limit="1.00" upper_limit="482.00"/>
                    <measurement group_id="O6" value="98.00" lower_limit="1.00" upper_limit="304.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="265.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-ALL DOUBLES, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.50" lower_limit="1.00" upper_limit="438.50"/>
                    <measurement group_id="O2" value="70.00" lower_limit="1.00" upper_limit="258.00"/>
                    <measurement group_id="O3" value="167.50" lower_limit="43.00" upper_limit="336.00"/>
                    <measurement group_id="O4" value="147.50" lower_limit="1.00" upper_limit="301.00"/>
                    <measurement group_id="O5" value="163.00" lower_limit="1.00" upper_limit="307.00"/>
                    <measurement group_id="O6" value="173.50" lower_limit="1.00" upper_limit="434.00"/>
                    <measurement group_id="O7" value="100.00" lower_limit="1.00" upper_limit="358.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-CD40L, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="54.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="58.50"/>
                    <measurement group_id="O3" value="49.00" lower_limit="1.00" upper_limit="101.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="1.00" upper_limit="52.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="1.00" upper_limit="60.00"/>
                    <measurement group_id="O6" value="1.00" lower_limit="1.00" upper_limit="102.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="113.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-CD40L, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.00" upper_limit="81.50"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.50" lower_limit="1.00" upper_limit="60.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="1.00" upper_limit="190.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="1.00" upper_limit="95.50"/>
                    <measurement group_id="O6" value="49.50" lower_limit="1.00" upper_limit="98.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-CD40L, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="52.00"/>
                    <measurement group_id="O3" value="51.00" lower_limit="1.00" upper_limit="82.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="1.00" upper_limit="7.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="1.00" upper_limit="56.00"/>
                    <measurement group_id="O6" value="1.00" lower_limit="1.00" upper_limit="51.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="49.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-CD40L, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="100.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="49.00"/>
                    <measurement group_id="O3" value="48.00" lower_limit="1.00" upper_limit="101.00"/>
                    <measurement group_id="O4" value="25.50" lower_limit="1.00" upper_limit="97.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="1.00" upper_limit="78.00"/>
                    <measurement group_id="O6" value="26.50" lower_limit="1.00" upper_limit="135.00"/>
                    <measurement group_id="O7" value="3.50" lower_limit="1.00" upper_limit="149.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IFN-γ, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="107.00"/>
                    <measurement group_id="O2" value="21.50" lower_limit="1.00" upper_limit="108.00"/>
                    <measurement group_id="O3" value="97.00" lower_limit="1.00" upper_limit="204.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="1.00" upper_limit="103.00"/>
                    <measurement group_id="O5" value="52.50" lower_limit="1.00" upper_limit="150.00"/>
                    <measurement group_id="O6" value="50.50" lower_limit="1.00" upper_limit="155.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="113.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IFN-γ, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.00" lower_limit="1.00" upper_limit="156.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="50.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="131.00"/>
                    <measurement group_id="O4" value="50.00" lower_limit="1.00" upper_limit="155.00"/>
                    <measurement group_id="O5" value="49.50" lower_limit="1.00" upper_limit="167.50"/>
                    <measurement group_id="O6" value="48.50" lower_limit="1.00" upper_limit="141.00"/>
                    <measurement group_id="O7" value="49.00" lower_limit="1.00" upper_limit="192.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IFN-γ, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.50" lower_limit="1.00" upper_limit="159.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="76.00"/>
                    <measurement group_id="O3" value="54.00" lower_limit="1.00" upper_limit="155.00"/>
                    <measurement group_id="O4" value="29.00" lower_limit="1.00" upper_limit="107.00"/>
                    <measurement group_id="O5" value="50.00" lower_limit="1.00" upper_limit="303.00"/>
                    <measurement group_id="O6" value="49.00" lower_limit="1.00" upper_limit="128.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="51.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IFN-γ, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" lower_limit="1.00" upper_limit="122.50"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="130.00"/>
                    <measurement group_id="O3" value="60.00" lower_limit="1.00" upper_limit="111.00"/>
                    <measurement group_id="O4" value="82.00" lower_limit="1.00" upper_limit="277.00"/>
                    <measurement group_id="O5" value="98.00" lower_limit="1.00" upper_limit="313.00"/>
                    <measurement group_id="O6" value="94.50" lower_limit="1.00" upper_limit="129.00"/>
                    <measurement group_id="O7" value="50.50" lower_limit="1.00" upper_limit="198.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Antigen-specific CD8 T-cells</title>
        <description>Among expressed immune markers were interleukin-2 (IL-2) and tumour necrosis factor-alpha (TNF-α).</description>
        <time_frame>At Days 0, 10, 21 and 42 post-vaccination</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm , at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Da y 189 for subjects in Subs t I and at Day 0, Day 21 and Da y 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Antigen-specific CD8 T-cells</title>
          <description>Among expressed immune markers were interleukin-2 (IL-2) and tumour necrosis factor-alpha (TNF-α).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>CD8+ T-cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD8-IL-2, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.00" lower_limit="1.00" upper_limit="152.00"/>
                    <measurement group_id="O2" value="20.00" lower_limit="1.00" upper_limit="128.00"/>
                    <measurement group_id="O3" value="56.00" lower_limit="1.00" upper_limit="238.00"/>
                    <measurement group_id="O4" value="34.50" lower_limit="1.00" upper_limit="198.00"/>
                    <measurement group_id="O5" value="7.50" lower_limit="1.00" upper_limit="90.00"/>
                    <measurement group_id="O6" value="25.00" lower_limit="1.00" upper_limit="179.00"/>
                    <measurement group_id="O7" value="4.00" lower_limit="1.00" upper_limit="62.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IL-2, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.50" lower_limit="1.00" upper_limit="154.50"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="195.00"/>
                    <measurement group_id="O3" value="50.00" lower_limit="1.00" upper_limit="166.00"/>
                    <measurement group_id="O4" value="64.00" lower_limit="1.00" upper_limit="235.00"/>
                    <measurement group_id="O5" value="1.50" lower_limit="1.00" upper_limit="155.00"/>
                    <measurement group_id="O6" value="71.50" lower_limit="1.00" upper_limit="231.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IL-2, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="46.00"/>
                    <measurement group_id="O2" value="19.00" lower_limit="1.00" upper_limit="97.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="192.00"/>
                    <measurement group_id="O4" value="23.00" lower_limit="1.00" upper_limit="211.00"/>
                    <measurement group_id="O5" value="24.00" lower_limit="1.00" upper_limit="173.00"/>
                    <measurement group_id="O6" value="38.00" lower_limit="1.00" upper_limit="304.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="73.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IL-2, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.50" lower_limit="1.00" upper_limit="291.50"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="260.00"/>
                    <measurement group_id="O3" value="98.50" lower_limit="1.00" upper_limit="248.00"/>
                    <measurement group_id="O4" value="24.50" lower_limit="1.00" upper_limit="151.00"/>
                    <measurement group_id="O5" value="47.00" lower_limit="1.00" upper_limit="153.00"/>
                    <measurement group_id="O6" value="29.50" lower_limit="1.00" upper_limit="365.00"/>
                    <measurement group_id="O7" value="25.00" lower_limit="1.00" upper_limit="262.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-TNF-α, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" lower_limit="1.00" upper_limit="105.00"/>
                    <measurement group_id="O2" value="19.50" lower_limit="1.00" upper_limit="154.50"/>
                    <measurement group_id="O3" value="51.00" lower_limit="1.00" upper_limit="241.00"/>
                    <measurement group_id="O4" value="50.00" lower_limit="1.00" upper_limit="155.00"/>
                    <measurement group_id="O5" value="85.50" lower_limit="10.00" upper_limit="267.00"/>
                    <measurement group_id="O6" value="77.00" lower_limit="1.00" upper_limit="155.00"/>
                    <measurement group_id="O7" value="10.50" lower_limit="1.00" upper_limit="96.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-TNF-α, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.50" lower_limit="1.00" upper_limit="242.00"/>
                    <measurement group_id="O2" value="25.00" lower_limit="1.00" upper_limit="150.00"/>
                    <measurement group_id="O3" value="77.00" lower_limit="1.00" upper_limit="171.00"/>
                    <measurement group_id="O4" value="49.00" lower_limit="1.00" upper_limit="198.00"/>
                    <measurement group_id="O5" value="82.00" lower_limit="1.00" upper_limit="210.00"/>
                    <measurement group_id="O6" value="51.50" lower_limit="1.00" upper_limit="198.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="124.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-TNF-α, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" lower_limit="1.00" upper_limit="272.50"/>
                    <measurement group_id="O2" value="51.00" lower_limit="1.00" upper_limit="100.00"/>
                    <measurement group_id="O3" value="57.00" lower_limit="1.00" upper_limit="220.00"/>
                    <measurement group_id="O4" value="23.00" lower_limit="1.00" upper_limit="374.00"/>
                    <measurement group_id="O5" value="100.00" lower_limit="1.00" upper_limit="388.00"/>
                    <measurement group_id="O6" value="48.00" lower_limit="1.00" upper_limit="289.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="97.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-TNF-α, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.50" lower_limit="1.00" upper_limit="386.50"/>
                    <measurement group_id="O2" value="101.00" lower_limit="1.00" upper_limit="258.00"/>
                    <measurement group_id="O3" value="157.00" lower_limit="50.00" upper_limit="226.00"/>
                    <measurement group_id="O4" value="76.00" lower_limit="1.00" upper_limit="301.00"/>
                    <measurement group_id="O5" value="163.00" lower_limit="1.00" upper_limit="307.00"/>
                    <measurement group_id="O6" value="110.00" lower_limit="3.00" upper_limit="434.00"/>
                    <measurement group_id="O7" value="49.00" lower_limit="1.00" upper_limit="163.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cytokine-positive CD8 T-cells Frequency</title>
        <description>Among expressed immune markers were interleukin-2 (IL-2), interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 - ligand (CD40-L). Descriptive comparison of the CMI response after Dose 1 and Dose 2 of the monovalent candidate pandemic influenza A vaccine. CMI response was determined in terms of the proportion of lymphocytes (CD4+ and CD8+ per million T cells) activated in vitro by the vaccine antigen on Days 10 and 21 after the Dose 1 and on Day 21 after Dose 2 as compared to Day 0 (pre-vaccination). The results were calculated based on the individual difference between each post-vaccination timepoint (Day 10, Day 21, Day 42) and Day 0.</description>
        <time_frame>At Days 10, 21 and 42 post-vaccination</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm , at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Da y 189 for subjects in Subs t I and at Day 0, Day 21 and Da y 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cytokine-positive CD8 T-cells Frequency</title>
          <description>Among expressed immune markers were interleukin-2 (IL-2), interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α) and cluster of differentiation 40 - ligand (CD40-L). Descriptive comparison of the CMI response after Dose 1 and Dose 2 of the monovalent candidate pandemic influenza A vaccine. CMI response was determined in terms of the proportion of lymphocytes (CD4+ and CD8+ per million T cells) activated in vitro by the vaccine antigen on Days 10 and 21 after the Dose 1 and on Day 21 after Dose 2 as compared to Day 0 (pre-vaccination). The results were calculated based on the individual difference between each post-vaccination timepoint (Day 10, Day 21, Day 42) and Day 0.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>CD8+ T-cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="16"/>
                <count group_id="O7" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD8-ALL DOUBLES, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="16"/>
                    <count group_id="O7" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="-86.00" upper_limit="143.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-99.00" upper_limit="47.00"/>
                    <measurement group_id="O3" value="16.00" lower_limit="-145.00" upper_limit="152.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-50.00" upper_limit="100.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-234.00" upper_limit="155.00"/>
                    <measurement group_id="O6" value="4.00" lower_limit="-155.00" upper_limit="267.00"/>
                    <measurement group_id="O7" value="0.00" lower_limit="-21.00" upper_limit="49.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-ALL DOUBLES, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.00" lower_limit="-118.00" upper_limit="85.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-126.00" upper_limit="51.00"/>
                    <measurement group_id="O3" value="-31.00" lower_limit="-266.00" upper_limit="105.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-45.00" upper_limit="223.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-98.00" upper_limit="1.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-48.00" upper_limit="218.00"/>
                    <measurement group_id="O7" value="0.00" lower_limit="-37.00" upper_limit="59.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-ALL DOUBLES, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.50" lower_limit="-128.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="44.00" lower_limit="-99.00" upper_limit="99.00"/>
                    <measurement group_id="O3" value="-29.00" lower_limit="-50.00" upper_limit="335.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="0.00" upper_limit="204.00"/>
                    <measurement group_id="O5" value="-5.00" lower_limit="-188.00" upper_limit="126.00"/>
                    <measurement group_id="O6" value="94.00" lower_limit="-54.00" upper_limit="386.00"/>
                    <measurement group_id="O7" value="-1.50" lower_limit="-47.00" upper_limit="344.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-CD40L, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="16"/>
                    <count group_id="O7" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-50.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-50.00" upper_limit="48.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="103.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="109.00"/>
                    <measurement group_id="O6" value="24.00" lower_limit="-5.00" upper_limit="94.50"/>
                    <measurement group_id="O7" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-CD40L, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-48.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-1.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-18.00" upper_limit="60.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-48.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-86.00" upper_limit="62.00"/>
                    <measurement group_id="O7" value="0.00" lower_limit="-76.00" upper_limit="45.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-CD40L, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-48.00" upper_limit="47.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-49.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-7.00" upper_limit="46.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="81.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-81.00" upper_limit="135.00"/>
                    <measurement group_id="O7" value="0.00" lower_limit="-101.00" upper_limit="48.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IFN-γ, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="16"/>
                    <count group_id="O7" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-24.00" upper_limit="48.00"/>
                    <measurement group_id="O2" value="-35.00" lower_limit="-102.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-87.00" upper_limit="105.50"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-3.00" upper_limit="50.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-50.00" upper_limit="73.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-100.50" upper_limit="135.00"/>
                    <measurement group_id="O7" value="0.00" lower_limit="-42.00" upper_limit="49.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IFN-γ, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-63.00" upper_limit="76.00"/>
                    <measurement group_id="O2" value="-6.00" lower_limit="-96.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-159.00" upper_limit="54.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="105.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-96.00" upper_limit="73.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-50.00" upper_limit="74.00"/>
                    <measurement group_id="O7" value="0.00" lower_limit="-24.50" upper_limit="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IFN-γ, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" lower_limit="-48.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-96.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="49.00" lower_limit="-134.00" upper_limit="86.00"/>
                    <measurement group_id="O4" value="14.00" lower_limit="0.00" upper_limit="140.00"/>
                    <measurement group_id="O5" value="-50.00" lower_limit="-96.00" upper_limit="67.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-50.00" upper_limit="120.00"/>
                    <measurement group_id="O7" value="0.00" lower_limit="-124.00" upper_limit="124.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IL-2, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="16"/>
                    <count group_id="O7" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-103.00" upper_limit="59.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-38.00" upper_limit="47.00"/>
                    <measurement group_id="O3" value="2.50" lower_limit="-123.00" upper_limit="66.50"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-98.00" upper_limit="100.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-50.00" upper_limit="118.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-80.00" upper_limit="160.50"/>
                    <measurement group_id="O7" value="0.00" lower_limit="-21.00" upper_limit="96.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IL-2, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.00" lower_limit="-151.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-38.00" upper_limit="50.00"/>
                    <measurement group_id="O3" value="-1.00" lower_limit="-205.00" upper_limit="113.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="129.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-81.00" upper_limit="38.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-60.00" upper_limit="98.00"/>
                    <measurement group_id="O7" value="0.00" lower_limit="-16.00" upper_limit="78.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-IL-2, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.50" lower_limit="-106.00" upper_limit="97.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-69.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-46.00" upper_limit="247.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-67.00" upper_limit="112.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-13.00" upper_limit="98.00"/>
                    <measurement group_id="O6" value="46.00" lower_limit="-102.00" upper_limit="292.00"/>
                    <measurement group_id="O7" value="0.00" lower_limit="-45.00" upper_limit="147.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-TNF-α, DAY 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="16"/>
                    <count group_id="O7" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="-99.00" upper_limit="99.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-97.00" upper_limit="47.00"/>
                    <measurement group_id="O3" value="23.00" lower_limit="-49.50" upper_limit="121.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-48.00" upper_limit="194.00"/>
                    <measurement group_id="O5" value="-3.00" lower_limit="-140.00" upper_limit="46.00"/>
                    <measurement group_id="O6" value="-24.50" lower_limit="-127.50" upper_limit="114.50"/>
                    <measurement group_id="O7" value="0.00" lower_limit="0.00" upper_limit="47.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-TNF-α, DAY 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="16"/>
                    <count group_id="O7" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.50" lower_limit="-97.00" upper_limit="21.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-50.00" upper_limit="75.00"/>
                    <measurement group_id="O3" value="-7.00" lower_limit="-127.00" upper_limit="114.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-45.00" upper_limit="247.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-49.00" upper_limit="47.00"/>
                    <measurement group_id="O6" value="-24.50" lower_limit="-127.50" upper_limit="114.50"/>
                    <measurement group_id="O7" value="0.00" lower_limit="0.00" upper_limit="47.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-TNF-α, DAY 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-99.00" upper_limit="47.00"/>
                    <measurement group_id="O2" value="48.00" lower_limit="-69.00" upper_limit="159.00"/>
                    <measurement group_id="O3" value="74.00" lower_limit="-7.00" upper_limit="289.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-52.00" upper_limit="255.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-62.00" upper_limit="149.00"/>
                    <measurement group_id="O6" value="99.00" lower_limit="-34.00" upper_limit="243.00"/>
                    <measurement group_id="O7" value="24.00" lower_limit="-95.00" upper_limit="120.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</title>
        <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
        <time_frame>At Day 21 post Dose 2 (Day 42)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</title>
          <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9" lower_limit="40.1" upper_limit="77.8"/>
                    <measurement group_id="O2" value="36.0" lower_limit="25.8" upper_limit="50.2"/>
                    <measurement group_id="O3" value="31.0" lower_limit="21.3" upper_limit="45.1"/>
                    <measurement group_id="O4" value="20.0" lower_limit="15.2" upper_limit="26.2"/>
                    <measurement group_id="O5" value="63.1" lower_limit="45.3" upper_limit="87.9"/>
                    <measurement group_id="O6" value="38.0" lower_limit="26.7" upper_limit="54.1"/>
                    <measurement group_id="O7" value="26.0" lower_limit="20.0" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</title>
        <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
        <time_frame>At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)</title>
          <description>Anti-H9N2 antibody titers were expressed as Geometric Mean Titers (GMTs).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="22"/>
                <count group_id="O10" value="22"/>
                <count group_id="O11" value="20"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="24"/>
                <count group_id="O14" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" lower_limit="31.8" upper_limit="77.4"/>
                    <measurement group_id="O2" value="51.3" lower_limit="30.4" upper_limit="86.7"/>
                    <measurement group_id="O3" value="51.1" lower_limit="32.8" upper_limit="79.5"/>
                    <measurement group_id="O4" value="32.2" lower_limit="21.8" upper_limit="47.5"/>
                    <measurement group_id="O5" value="71.0" lower_limit="50.0" upper_limit="100.7"/>
                    <measurement group_id="O6" value="44.0" lower_limit="30.3" upper_limit="64.0"/>
                    <measurement group_id="O7" value="28.3" lower_limit="18.9" upper_limit="42.4"/>
                    <measurement group_id="O8" value="103.0" lower_limit="63.3" upper_limit="167.5"/>
                    <measurement group_id="O9" value="41.3" lower_limit="27.1" upper_limit="62.7"/>
                    <measurement group_id="O10" value="41.9" lower_limit="23.7" upper_limit="74.1"/>
                    <measurement group_id="O11" value="21.4" lower_limit="14.5" upper_limit="31.6"/>
                    <measurement group_id="O12" value="108.1" lower_limit="69.4" upper_limit="168.5"/>
                    <measurement group_id="O13" value="62.5" lower_limit="40.9" upper_limit="95.3"/>
                    <measurement group_id="O14" value="54.9" lower_limit="37.4" upper_limit="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</title>
        <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer &lt; 1:10 and a post-vaccination titre ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in postvaccination titer</description>
        <time_frame>At Day 21 post Dose 2 (Day 42)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</title>
          <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer &lt; 1:10 and a post-vaccination titre ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in postvaccination titer</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</title>
        <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer &lt; 1:10 and a post-vaccination titre ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in post-vaccination titer</description>
        <time_frame>At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against Influenza A Subtype H9N2</title>
          <description>Seroconversion rate was defined as the percentage of vaccinees who had a pre-vaccination HI titer &lt; 1:10 and a post-vaccination titre ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four-fold increase in post-vaccination titer</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="22"/>
                <count group_id="O10" value="22"/>
                <count group_id="O11" value="20"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="24"/>
                <count group_id="O14" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="12"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="17"/>
                    <measurement group_id="O13" value="15"/>
                    <measurement group_id="O14" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Factor for Influenza A Subtype H9N2</title>
        <description>Seroconversion factor defined as the fold increase in serum HI GMTs on day 21 post Dose 3 (Day 42) compared to day 0.</description>
        <time_frame>At Day 21 post Dose 2 (Day 42)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Influenza A Subtype H9N2</title>
          <description>Seroconversion factor defined as the fold increase in serum HI GMTs on day 21 post Dose 3 (Day 42) compared to day 0.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="4.3" upper_limit="9.0"/>
                    <measurement group_id="O2" value="4.9" lower_limit="3.5" upper_limit="6.8"/>
                    <measurement group_id="O3" value="4.3" lower_limit="2.9" upper_limit="6.4"/>
                    <measurement group_id="O4" value="2.9" lower_limit="2.3" upper_limit="3.7"/>
                    <measurement group_id="O5" value="8.3" lower_limit="5.8" upper_limit="11.9"/>
                    <measurement group_id="O6" value="4.9" lower_limit="3.4" upper_limit="7.2"/>
                    <measurement group_id="O7" value="3.7" lower_limit="2.8" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Factor for Influenza A Subtype H9N2</title>
        <description>Seroconversion factor was defined as the fold increase in serum HI GMTs on day 21 post Dose 3 (Day 210 for Subset 1 and Day 386 for Subset 2) compared to day 0.</description>
        <time_frame>At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Influenza A Subtype H9N2</title>
          <description>Seroconversion factor was defined as the fold increase in serum HI GMTs on day 21 post Dose 3 (Day 210 for Subset 1 and Day 386 for Subset 2) compared to day 0.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
          <units>Fold change</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="22"/>
                <count group_id="O10" value="22"/>
                <count group_id="O11" value="20"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="24"/>
                <count group_id="O14" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="3.6" upper_limit="8.2"/>
                    <measurement group_id="O2" value="8.3" lower_limit="5.1" upper_limit="13.5"/>
                    <measurement group_id="O3" value="7.9" lower_limit="4.6" upper_limit="13.6"/>
                    <measurement group_id="O4" value="4.4" lower_limit="3.1" upper_limit="6.4"/>
                    <measurement group_id="O5" value="10.5" lower_limit="7.0" upper_limit="15.6"/>
                    <measurement group_id="O6" value="6.4" lower_limit="4.3" upper_limit="9.6"/>
                    <measurement group_id="O7" value="4.3" lower_limit="2.8" upper_limit="6.4"/>
                    <measurement group_id="O8" value="11.9" lower_limit="6.4" upper_limit="21.9"/>
                    <measurement group_id="O9" value="5.5" lower_limit="3.5" upper_limit="8.6"/>
                    <measurement group_id="O10" value="5.6" lower_limit="3.2" upper_limit="9.6"/>
                    <measurement group_id="O11" value="2.8" lower_limit="1.9" upper_limit="4.2"/>
                    <measurement group_id="O12" value="11.2" lower_limit="5.9" upper_limit="21.1"/>
                    <measurement group_id="O13" value="2.0" lower_limit="1.3" upper_limit="3.2"/>
                    <measurement group_id="O14" value="5.4" lower_limit="3.0" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects Against H9N2</title>
        <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
        <time_frame>At Day 21 post Dose 2 (Day 42)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group:</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against H9N2</title>
          <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects Against H9N2</title>
        <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
        <time_frame>At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against H9N2</title>
          <description>Seroprotection rate was defined as the percentage of vaccinees with a serum HI titer ≥ 1:40 after vaccination (for each vaccine strain) that usually was accepted as indicating protection.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="22"/>
                <count group_id="O10" value="22"/>
                <count group_id="O11" value="20"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="24"/>
                <count group_id="O14" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="13"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="20"/>
                    <measurement group_id="O13" value="17"/>
                    <measurement group_id="O14" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Seroprotection Power Against H9N2</title>
        <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
        <time_frame>At Day 21 post Dose 2 (Day 42)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Seroprotection Power Against H9N2</title>
          <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="22"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="18"/>
                <count group_id="O12" value="20"/>
                <count group_id="O13" value="24"/>
                <count group_id="O14" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="14"/>
                    <measurement group_id="O13" value="9"/>
                    <measurement group_id="O14" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Seroprotection Power Against H9N2</title>
        <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
        <time_frame>At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Seroprotection Power Against H9N2</title>
          <description>Seroprotection power was defined as the proportion of subjects who were unprotected prior to the vaccination (HI titer &lt; 1:40 on day 0) and had a protective post-vaccination titer of ≥ 1:40.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="18"/>
                <count group_id="O12" value="20"/>
                <count group_id="O13" value="23"/>
                <count group_id="O14" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="11"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="17"/>
                    <measurement group_id="O13" value="16"/>
                    <measurement group_id="O14" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness, swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain which prevents normal everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm).</description>
        <time_frame>During the 4-days post Dose 1 (Days 0-3), post Dose 2 (Days 21-24) and across these doses</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVc) included all vaccinated subjects (for whom diary card was available).</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm , at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Da y 189 for subjects in Subs t I and at Day 0, Day 21 and Da y 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were pain, redness, swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain which prevents normal everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm).</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVc) included all vaccinated subjects (for whom diary card was available).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness (mm), Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness (mm), Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling (mm), Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (mm), Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness (mm), Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness (mm), Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling (mm), Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (mm), Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Across doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Across doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness (mm), Across doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness (mm), Across doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling (mm), Across doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (mm), Across doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness, swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain which prevents normal everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm).</description>
        <time_frame>During the 4 Days post Dose 3 (Days 189-192 for Subset 1 groups and Days 365-368 for Subset 2 groups)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVc) of Subsets, which included all vaccinated subjects (for whom the diary card was available).</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were pain, redness, swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain which prevents normal everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm).</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVc) of Subsets, which included all vaccinated subjects (for whom the diary card was available).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="24"/>
                <count group_id="O10" value="23"/>
                <count group_id="O11" value="22"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="26"/>
                <count group_id="O14" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness (mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness (mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling (mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = axillary temperature higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
        <time_frame>During the 4-days (Day 0-3) post Dose 1</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVc) included all vaccinated subjects (for whom diary card was available).</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm , at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Da y 189 for subjects in Subs t I and at Day 0, Day 21 and Da y 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = axillary temperature higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVc) included all vaccinated subjects (for whom diary card was available).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature (Axillary) (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature (Axillary) (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature (Axillary) (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = axillary temperature higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
        <time_frame>During the 4-days post Dose 2 (Days 21-24)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVc) included all vaccinated subjects (for whom diary card was available).</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm , at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Da y 189 for subjects in Subs t I and at Day 0, Day 21 and Da y 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = axillary temperature higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVc) included all vaccinated subjects (for whom diary card was available).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature (Axillary) (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature (Axillary) (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature (Axillary) (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = axillary temperature higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
        <time_frame>During the 4-Days (Day 0-3) across doses 1 and 2</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVc) included all vaccinated subjects (for whom diary card was available).</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Group</title>
            <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm , at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Group</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Da y 189 for subjects in Subs t I and at Day 0, Day 21 and Da y 365 for subjects in Subset 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = axillary temperature higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVc) included all vaccinated subjects (for whom diary card was available).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature (Axillary) (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature (Axillary) (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature (Axillary) (°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axilar temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = fever higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
        <time_frame>During the 4 Days post Dose 3 (Days 189-192 for Subset 1 groups and Days 365-368 for Subset 2 groups)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVc) of Subsets, which included all vaccinated subjects (for whom the diary card was available).</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axilar temperature higher than (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering and sweating. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 fever = fever higher than (&gt;) 39°C. Related symptom = symptom assessed by the investigator as being casually related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVc) of Subsets, which included all vaccinated subjects (for whom the diary card was available).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="24"/>
                <count group_id="O10" value="23"/>
                <count group_id="O11" value="22"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="26"/>
                <count group_id="O14" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited AEs</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
        <time_frame>During the 30-days post Dose 3 (Days 189-219 for Subset 1 groups and Days 365-395 for Subset 2 groups)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVc) of Subsets, which included all vaccinated subjects (for whom the diary card was available).</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited AEs</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVc) of Subsets, which included all vaccinated subjects (for whom the diary card was available).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="24"/>
                <count group_id="O10" value="23"/>
                <count group_id="O11" value="22"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="26"/>
                <count group_id="O14" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any unsolicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 unsolicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related unsolicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With SAEs</title>
        <description>A SAE was any untoward medical occurrence which resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, resulted in permanent of serious physical disability or incapacity, caused a congenital anomaly or birth defect in the offspring of a subject or might have put the subject at risk based on medical or scientific judgment or necessitated intervention to prevent such an event (e.q. invasive or malignant cancers, intensive treatment in an emergency room or at home for bronchospasm, blood dyscrasias, or convulsion that do not resulted in hospitalization).</description>
        <time_frame>Within the 365-day post-vaccination period (Days 0-364 for Subset 1 groups) and within the 395-day post-vaccination period (Days 0-394 for Subset 2 groups)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVc) of Subsets, which included all vaccinated subjects (for whom the diary card was available).</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With SAEs</title>
          <description>A SAE was any untoward medical occurrence which resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, resulted in permanent of serious physical disability or incapacity, caused a congenital anomaly or birth defect in the offspring of a subject or might have put the subject at risk based on medical or scientific judgment or necessitated intervention to prevent such an event (e.q. invasive or malignant cancers, intensive treatment in an emergency room or at home for bronchospasm, blood dyscrasias, or convulsion that do not resulted in hospitalization).</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVc) of Subsets, which included all vaccinated subjects (for whom the diary card was available).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="24"/>
                <count group_id="O10" value="23"/>
                <count group_id="O11" value="22"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="26"/>
                <count group_id="O14" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAEs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="24"/>
                    <count group_id="O10" value="23"/>
                    <count group_id="O11" value="22"/>
                    <count group_id="O12" value="23"/>
                    <count group_id="O13" value="26"/>
                    <count group_id="O14" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 SAEs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                    <count group_id="O13" value="0"/>
                    <count group_id="O14" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any SAEs</title>
        <description>A SAE was any untoward medical occurrence which resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, resulted in permanent of serious physical disability or incapacity, caused a congenital anomaly or birth defect in the offspring of a subject or might have put the subject at risk based on medical or scientific judgment or necessitated intervention to prevent such an event (e.q. invasive or malignant cancers, intensive treatment in an emergency room or at home for bronchospasm, blood dyscrasias, or convulsion that do not resulted in hospitalization). Only Subset 2 groups had available data for the specified time frame.</description>
        <time_frame>Up to 30-day post Dose 3 (Days 365-394)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort (TVc) of Subset 2, which included all vaccinated subjects (for whom the diary card was available).</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any SAEs</title>
          <description>A SAE was any untoward medical occurrence which resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, resulted in permanent of serious physical disability or incapacity, caused a congenital anomaly or birth defect in the offspring of a subject or might have put the subject at risk based on medical or scientific judgment or necessitated intervention to prevent such an event (e.q. invasive or malignant cancers, intensive treatment in an emergency room or at home for bronchospasm, blood dyscrasias, or convulsion that do not resulted in hospitalization). Only Subset 2 groups had available data for the specified time frame.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort (TVc) of Subset 2, which included all vaccinated subjects (for whom the diary card was available).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Antibody Persistence</title>
        <description>Antibody persistence was evaluated in terms of seroprotection rate (SPR) against influenza A subtype H9N2 and seroconversion rate (SCR) against influenza A subtype H9N2.</description>
        <time_frame>At Days 189 and 365</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibody Persistence</title>
          <description>Antibody persistence was evaluated in terms of seroprotection rate (SPR) against influenza A subtype H9N2 and seroconversion rate (SCR) against influenza A subtype H9N2.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="23"/>
                <count group_id="O10" value="22"/>
                <count group_id="O11" value="20"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="25"/>
                <count group_id="O14" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SPR, Day 189</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                    <count group_id="O10" value="22"/>
                    <count group_id="O11" value="20"/>
                    <count group_id="O12" value="23"/>
                    <count group_id="O13" value="25"/>
                    <count group_id="O14" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="14"/>
                    <measurement group_id="O13" value="7"/>
                    <measurement group_id="O14" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPR, Day 365</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="22"/>
                    <count group_id="O10" value="22"/>
                    <count group_id="O11" value="20"/>
                    <count group_id="O12" value="23"/>
                    <count group_id="O13" value="24"/>
                    <count group_id="O14" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="13"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="20"/>
                    <measurement group_id="O13" value="17"/>
                    <measurement group_id="O14" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR, Day 189</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                    <count group_id="O10" value="22"/>
                    <count group_id="O11" value="20"/>
                    <count group_id="O12" value="23"/>
                    <count group_id="O13" value="25"/>
                    <count group_id="O14" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="9"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR, Day 365</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="22"/>
                    <count group_id="O10" value="22"/>
                    <count group_id="O11" value="20"/>
                    <count group_id="O12" value="23"/>
                    <count group_id="O13" value="24"/>
                    <count group_id="O14" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="12"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="17"/>
                    <measurement group_id="O13" value="15"/>
                    <measurement group_id="O14" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor (SCF) for Influenza A Subtype H9N2.</title>
        <description>SCF was defined as the fold increase in serum HI GMTs at the post-vaccination time points compared to Day 0, for each vaccine strain.</description>
        <time_frame>At Days 189 and 365</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>SB218352_15 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O2">
            <title>SB218352_8 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O3">
            <title>SB218352_4 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O4">
            <title>SB218352_2 Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O5">
            <title>SB218352_8AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O6">
            <title>SB218352_4AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O7">
            <title>SB218352_2AL Subset 1</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189.</description>
          </group>
          <group group_id="O8">
            <title>SB218352_15 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O9">
            <title>SB218352_8 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O10">
            <title>SB218352_4 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O11">
            <title>SB218352_2 Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O12">
            <title>SB218352_8AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O13">
            <title>SB218352_4AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
          <group group_id="O14">
            <title>SB218352_2AL Subset 2</title>
            <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 365.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor (SCF) for Influenza A Subtype H9N2.</title>
          <description>SCF was defined as the fold increase in serum HI GMTs at the post-vaccination time points compared to Day 0, for each vaccine strain.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all evaluable subjects for whom data concerning persistence of the immune response induced by the vaccine were available for the specified time points.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="23"/>
                <count group_id="O10" value="22"/>
                <count group_id="O11" value="20"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="25"/>
                <count group_id="O14" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCF, Day 189</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="23"/>
                    <count group_id="O10" value="22"/>
                    <count group_id="O11" value="20"/>
                    <count group_id="O12" value="23"/>
                    <count group_id="O13" value="25"/>
                    <count group_id="O14" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.9" upper_limit="4.5"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.2" upper_limit="5.2"/>
                    <measurement group_id="O3" value="3.7" lower_limit="2.1" upper_limit="6.5"/>
                    <measurement group_id="O4" value="2.3" lower_limit="1.7" upper_limit="3.1"/>
                    <measurement group_id="O5" value="3.2" lower_limit="2.1" upper_limit="5.0"/>
                    <measurement group_id="O6" value="3.2" lower_limit="2.1" upper_limit="4.9"/>
                    <measurement group_id="O7" value="1.8" lower_limit="1.3" upper_limit="2.5"/>
                    <measurement group_id="O8" value="3.3" lower_limit="1.8" upper_limit="6.1"/>
                    <measurement group_id="O9" value="2.7" lower_limit="1.5" upper_limit="4.9"/>
                    <measurement group_id="O10" value="2.1" lower_limit="1.1" upper_limit="4.1"/>
                    <measurement group_id="O11" value="1.5" lower_limit="1.1" upper_limit="1.9"/>
                    <measurement group_id="O12" value="5.8" lower_limit="3.4" upper_limit="10.0"/>
                    <measurement group_id="O13" value="2.2" lower_limit="1.3" upper_limit="3.8"/>
                    <measurement group_id="O14" value="1.7" lower_limit="1.1" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCF, Day 365</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="22"/>
                    <count group_id="O9" value="22"/>
                    <count group_id="O10" value="22"/>
                    <count group_id="O11" value="20"/>
                    <count group_id="O12" value="23"/>
                    <count group_id="O13" value="24"/>
                    <count group_id="O14" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="2.1" upper_limit="4.6"/>
                    <measurement group_id="O2" value="5.4" lower_limit="3.5" upper_limit="8.5"/>
                    <measurement group_id="O3" value="4.3" lower_limit="2.5" upper_limit="7.4"/>
                    <measurement group_id="O4" value="2.1" lower_limit="1.4" upper_limit="3.0"/>
                    <measurement group_id="O5" value="4.3" lower_limit="3.0" upper_limit="6.1"/>
                    <measurement group_id="O6" value="2.9" lower_limit="1.9" upper_limit="4.2"/>
                    <measurement group_id="O7" value="2.1" lower_limit="1.4" upper_limit="3.1"/>
                    <measurement group_id="O8" value="11.9" lower_limit="6.4" upper_limit="21.9"/>
                    <measurement group_id="O9" value="5.5" lower_limit="3.5" upper_limit="8.6"/>
                    <measurement group_id="O10" value="5.6" lower_limit="3.2" upper_limit="9.6"/>
                    <measurement group_id="O11" value="2.8" lower_limit="1.9" upper_limit="4.2"/>
                    <measurement group_id="O12" value="11.2" lower_limit="5.9" upper_limit="21.1"/>
                    <measurement group_id="O13" value="7.5" lower_limit="4.9" upper_limit="11.5"/>
                    <measurement group_id="O14" value="5.4" lower_limit="3.0" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and general symptoms: during the 4-day (Days 0-3) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-vaccination period; SAEs: up to Day 51.</time_frame>
      <desc>One subject from the SB218352_15 Group reported both SAE(s) included in the Adverse Events section.</desc>
      <group_list>
        <group group_id="E1">
          <title>SB218352_15 Group</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="E2">
          <title>SB218352_8 Group</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="E3">
          <title>SB218352_4 Group</title>
          <description>Male and fem le subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm , at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="E4">
          <title>SB218352_2 Group</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="E5">
          <title>SB218352_8AL Group</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at D y 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="E6">
          <title>SB218352_4AL Group</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Day 189 for subjects in Subset I and at Day 0, Day 21 and Day 365 for subjects in Subset 2.</description>
        </group>
        <group group_id="E7">
          <title>SB218352_2AL Group</title>
          <description>Male and female subjects over 60 years of age, healthy or with underlying disease, received 3 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-domina nt arm, at Day 0, Day 21 and Da y 189 for subjects in Subs t I and at Day 0, Day 21 and Da y 365 for subjects in Subset 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="55"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" events="22" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E6" events="20" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E7" events="20" subjects_affected="12" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" events="15" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E6" events="15" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E7" events="13" subjects_affected="9" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" events="11" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E7" events="9" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E6" events="8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E5" events="14" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E7" events="11" subjects_affected="8" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" events="18" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E6" events="14" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E7" events="12" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

